Submit an Article > Register > Login >

Annali

dell'Istituto Superiore di Sanità

Search
Vol. 56 No. 4 (2020)
Original Articles
2020-12-28
Share on

Epidemiological data and treatment strategies in children with severe haemophilia in Italy

Authors

Francesca Abbonizio , Hamisa J. Hassan , Elena Santagostino , on behalf of the Italian Association of Haemophilia Centres , Romano Arcieri , Mauro Biffoni , Adele Giampaolo

Keywords: Child patients, Haemophilia A, Haemophilia B, Therapeutic treatment

Abstract

Objectives. In a period of important therapeutic changes in the field of haemophilia
care, we provide updated statistics on children with severe haemophilia (0-12 years of
age) in Italy.
Methods. Data presented are from the Italian National Registry of Congenital Coagulopathies
(NRCC) – survey 2017.
Results. Children with severe Haemophilia A (HA) were 242, those with severe haemophilia
B (HB) 48. Prophylaxis was adopted in 92.1% of individuals with severe HA and
88.6% with severe HB. Thirty-nine children (14.8%) were on treatment for inhibitors.
FVIII prescribed to children with severe HA represented 11.1% of the total consumption,
of which 4.6% was extended half-life (EHL). FIX given to children with HB accounted
for 7.2% of the total FIX, of which 19.1% was EHL-FIX.
Conclusion. The paediatric population analysed is characterized by a great adherence
to therapy, so this data may constitute a benchmark for use of new, alternative therapies
in the coming years.

References

  1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801-1809.
  2. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779.
  3. Chalmers EA, Alamelu J, Collins PW, Mathias M, Payne J, Richards M, et al. Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: A national cohort study. Haemophilia. 2018;24(4):641-647. doi: 10.1111/hae.13461.
  4. Kasper CK, Lin JC. Prevalence of sporadic and familial haemophilia. Haemophilia. 2007;13(1):90-97.
  5. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011;(9):CD003429. doi: 10.1002/14651858.CD003429.pub4.
  6. Rocino A, Coppola A, Franchini M, Castaman G, Santoro C, Zanon E, et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus. 2014;12(4):575-598. doi: 10.2450/2014.0223-14.
  7. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47. doi:10.1111/j.1365-2516.2012.02909.x.
  8. Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence. 2017;11:1677-1686. doi: 10.2147/PPA.S139851.
  9. Franchini M, Coppola A, Rocino A, Santagostino E, Tagliaferri A, Zanon E, et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update. Semin Thromb Hemost. 2013;39(7):752-766. doi: 10.1055/s-0033-1356715.
  10. Franchini M, Santoro C, Coppola A. Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature review. Thromb Haemost. 2016;116(1):201-203. doi: 10.1160/TH16-02-0116.
  11. Athale AH, Marcucci M, Iorio A. Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. Cochrane Database Syst Rev. 2014;24(4):CD010561. doi: 10.1002/14651858.CD010561.pub2.
  12. Matino D, Makris M, Dwan K, D'Amico R, Iorio A. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2015;16(12):CD004449. doi: 10.1002/14651858.CD004449.pub4.
  13. Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570-1574. doi: 10.1038/nm.2942.
  14. Iorio A, Oliovecchio E, Morfini M, Mannucci PM; Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia. 2008;14(3):444-453. doi: 10.1111/j.1365-2516.2008.01679.x. Erratum in: Haemophilia. 2009;15(2):637.
  15. Abbonizio F, Hassan HJ, Riccioni R, Santagostino E, Arcieri R, Giampaolo A; Italian Association of Haemophilia Centres. New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey. Blood Transf. 2019; doi 10.2450/2019.0211-18.
  16. Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E. Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018;24(3):348-358. doi: 10.1111/hae.13438.
  17. Mahlangu JN. Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B. Ther Adv Hematol. 2018;9(11):335-346. doi: 10.1177/2040620718802606.
  18. Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171(8):540-546. doi: 10.7326/M19-1208.
  19. Berntorp E, Dolan G, Hay C, Linari S, Santagostino E, Tosetto A, et al. European retrospective study of real-life haemophilia treatment. Haemophilia. 2017;23(1):105-114. doi: 10.1111/hae.13111.
  20. Mason JA, Parikh S, Tran H, Rowell J, McRae S. Australian multicentre study of current real-world prophylaxis practice in severe and moderate haemophilia A and B. Haemophilia. 2018;24(2):253-260. doi: 10.1111/hae.13375.
  21. Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol. 2010;150(5):515-528. doi:10.1111/j.1365-141.2010.08263.x.
  22. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818. doi: 10.1056/NEJMoa1703068.
  23. Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol. 2019;102(2):111-122. doi: 10.1111/ejh.13193.

Downloads

PDF
Authors

Francesca Abbonizio

Hamisa J. Hassan

Elena Santagostino

on behalf of the Italian Association of Haemophilia Centres

Romano Arcieri

Mauro Biffoni

Adele Giampaolo - Istituto Superiore di Sanità

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright

Copyright (c) 2020 Annali dell'Istituto Superiore di Sanità

How to Cite
Abbonizio, F. ., Hassan, H. J. ., Santagostino, E., Italian Association of Haemophilia Centres, on behalf of the ., Arcieri, R. ., Biffoni, M., & Giampaolo, A. (2020). Epidemiological data and treatment strategies in children with severe haemophilia in Italy. Annali dell’Istituto Superiore Di Sanità, 56(4). Retrieved from https://annali.iss.it/index.php/anna/article/view/1021
  • Abstract viewed - 283 times
  • PDF downloaded - 204 times